<p>The cost-effectiveness plane shows the efficiency frontiers for the univariate sensitivity analyses in which the prevalence of urinary tract infection was varied by plus and minus 10% and 20%.</p
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 15%....
<p>The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness e...
Showing the iterations from the probabilistic sensitivity analysis with cost difference along the y-...
<p>Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...
According to economic principles an inappropriate prescription is the choice of an antimicrobial wit...
<p>The investment costs in millions in US$ (2007) are depicted on the ho...
<p>The black dot indicates the point estimate of the ICER (1.6 prevented UTIs less and €247 more cos...
Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four scree...
<p>The sensitivity analysis recalculates the net expected cost of each strategy (Scr vs. uNGAL+Scr),...
<p>Cost-effectiveness plane for DCV/ASV versus PR: The cost-effectiveness plane represents the base ...
<p>The figure shows the distribution of cost-effectiveness pairs on the cost-effectiveness plane.</p
<p>Cost-effectiveness plane (upper) and acceptability curve (lower) for perceived health (VAS).</p
Results of a univariate sensitivity analysis of key variables on cost per DALY averted.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 5%.<...
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 15%....
<p>The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness e...
Showing the iterations from the probabilistic sensitivity analysis with cost difference along the y-...
<p>Cost-effectiveness plane presenting all non-dominated and selected dominated screening protocols ...
According to economic principles an inappropriate prescription is the choice of an antimicrobial wit...
<p>The investment costs in millions in US$ (2007) are depicted on the ho...
<p>The black dot indicates the point estimate of the ICER (1.6 prevented UTIs less and €247 more cos...
Cost-effectiveness plane comparing the effectiveness of status quo (no screening) and the four scree...
<p>The sensitivity analysis recalculates the net expected cost of each strategy (Scr vs. uNGAL+Scr),...
<p>Cost-effectiveness plane for DCV/ASV versus PR: The cost-effectiveness plane represents the base ...
<p>The figure shows the distribution of cost-effectiveness pairs on the cost-effectiveness plane.</p
<p>Cost-effectiveness plane (upper) and acceptability curve (lower) for perceived health (VAS).</p
Results of a univariate sensitivity analysis of key variables on cost per DALY averted.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 5%.<...
Cost-effectiveness plane in incremental number of treatment success and incremental cost.</p
Sensitivity analysis results evaluating cost-effectiveness of Histoplasma antigen prevalence of 15%....
<p>The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness e...
View in ORKG
DOI